Delivery Order SPE2DB20D3101-SPE2DB25FRUJ0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) at a ceiling value of $2,378.33. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on August 29, 2025, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $4,983.09 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units), with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $10,304.26. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement practices. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $19,403.29. This firm fixed-price delivery order, with an ultimate completion date of August 15, 2025, represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $45.5K delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price arrangement with a ceiling value of $28,746.00. This non-set-aside competitive award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through...
- The Defense Logistics Agency awarded a delivery order valued at $7,437.20 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office, with performance occurring at the company's headquarters in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,376.00 to supply Gemtesa 75 mg tablets (90-count packaging) with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $42,751.81. This non-set-aside delivery order is expected to be completed by August 1, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child award under the company's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Gemtesa 75 mg tablets (30-count units) with a ceiling value of $7,558.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The contract was competitively awarded with no set-aside designation and...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRUJ0Delivery Order
The Defense Logistics Agency awarded a $7,772.26 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). The contract represents a firm fixed price, non-set-aside award with an ultimate completion date of September 4, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a significant federal contract portfolio with the Defense Logistics Agency focused on supplying pharmaceutical products and medical supplies to military and veteran healthcare systems. The company's competitively awarded contracts with DLA demonstrate consistent capability in fulfilling federal medical procurement requirements across diverse therapeutic domains, ranging from specialty medications to generic drugs and medical devices. This delivery order for Gemtesa, a pharmaceutical product used in treating overactive bladder, exemplifies the vendor's role as a critical supplier within the federal medical supply chain supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.8k | 9/3/25 |